JGC
ZBIO

J. Goldman & Co’s Zenas BioPharma ZBIO Stock Holding History

J. Goldman & Co’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$719K Buy
+36,797
New +$826K 0.02% 461

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

J. Goldman & Co's ZBIO Position: Q1 2026 in Review

J. Goldman & Co opened a new position in Zenas BioPharma (ZBIO) in Q1 2026: 36,797 shares worth $719K. The stake represents 0.02% of the portfolio and ranks #461 among its holdings.

139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • J. Goldman & Co held 36,797 shares of Zenas BioPharma worth $719K as of Q1 2026.
  • Zenas BioPharma was a new J. Goldman & Co position in Q1 2026.
  • Zenas BioPharma made up 0.02% of J. Goldman & Co's portfolio in Q1 2026, its #461 holding.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.